Oxigene (OXGN) shares tumble over 35% after hours following a mixed report on its Phase 2 study...

|By:, SA News Editor

Oxigene (OXGN) shares tumble over 35% after hours following a mixed report on its Phase 2 study of its cancer drug Zybrestat. Although tests appear to show some improvement when combined with other treatments, the drug shows no discernible survival benefit in stand-alone form.